Local application of bacteria improves safety of Salmonella-mediated tumor therapy and retains advantages of systemic infection.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractCancer is a devastating disease and a large socio-economic burden. Novel therapeutic solutions are on the rise, although a cure remains elusive. Application of microorganisms represents an ancient therapeutic strategy, lately revoked and refined via simultaneous attenuation and amelioration of pathogenic properties. Salmonella Typhimurium has prevailed in preclinical development. Yet, using virulent strains for systemic treatment might cause severe side effects. In the present study, we highlight a modified strain based on Salmonella Typhimurium UK-1 expressing hexa-acylated Lipid A. We corroborate improved anti-tumor properties of this strain and investigate to which extent an intra-tumoral (i.t.) route of infection could help improve safety and retain advantages of systemic intravenous (i.v.) application. Our results show that i.t. infection exhibits therapeutic efficacy against CT26 and F1.A11 tumors similar to a systemic route of inoculation. Moreover, i.t. application allows extensive dose titration without compromising tumor colonization. Adverse colonization of healthy organs was generally reduced via i.t. infection and accompanied by less body weight loss of the murine host. Despite local application, adjuvanticity remained, and a CT26-specific CD8+ T cell response was effectively stimulated. Most interestingly, also secondary tumors could be targeted with this strategy, thereby extending the unique tumor targeting ability of Salmonella. The i.t. route of inoculation may reap the benefits of systemic infection and aid in safety assurance while directing potency of an oncolytic vector to where it is most needed, namely the primary tumor.
CitationLocal application of bacteria improves safety of Salmonella-mediated tumor therapy and retains advantages of systemic infection. 2017 Oncotarget
AffiliationHelmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
- B cells are required for tumor-targeting Salmonella in host.
- Authors: Lee CH, Hsieh JL, Wu CL, Hsu HC, Shiau AL
- Issue date: 2011 Dec
- T cell augments the antitumor activity of tumor-targeting Salmonella.
- Authors: Lee CH, Hsieh JL, Wu CL, Hsu PY, Shiau AL
- Issue date: 2011 May
- Salmonella typhimurium Suppresses Tumor Growth via the Pro-Inflammatory Cytokine Interleukin-1β.
- Authors: Kim JE, Phan TX, Nguyen VH, Dinh-Vu HV, Zheng JH, Yun M, Park SG, Hong Y, Choy HE, Szardenings M, Hwang W, Park JA, Park S, Im SH, Min JJ
- Issue date: 2015
- Optimizing Salmonella enterica serovar Typhimurium for bacteria-mediated tumor therapy.
- Authors: Felgner S, Kocijancic D, Frahm M, Curtiss R 3rd, Erhardt M, Weiss S
- Issue date: 2016
- Therapeutic benefit of Salmonella attributed to LPS and TNF-α is exhaustible and dictated by tumor susceptibility.
- Authors: Kocijancic D, Leschner S, Felgner S, Komoll RM, Frahm M, Pawar V, Weiss S
- Issue date: 2017 May 30